Aspira Women'S Health INC. (AWHL) — 8-K Filings

All 8-K filings from Aspira Women'S Health INC.. Browse 46 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (46)

Aspira Women's Health Files 8-K — Dec 31, 2025 Risk: low
Aspira Women's Health Inc. filed an 8-K on December 29, 2025, reporting on events that occurred on the same date. The filing is a current report under Regulatio
8-K Filing — Dec 23, 2025
8-K Filing — Dec 22, 2025
Aspira Women's Health Files 8-K — Oct 15, 2025 Risk: low
On October 14, 2025, Aspira Women's Health Inc. filed an 8-K report. The filing indicates that the company's principal executive offices are located at 12117 Be
Aspira Women's Health Files 8-K on Agreements and Equity Sales — Sep 25, 2025 Risk: medium
Aspira Women's Health Inc. filed an 8-K on September 25, 2025, reporting on events that occurred on September 19, 2025. The filing indicates an entry into a mat
Aspira Women's Health Files 8-K — Sep 18, 2025 Risk: medium
On September 16, 2025, Aspira Women's Health Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securi
Aspira Women's Health: Director Departs, New Director Appointed — Sep 3, 2025 Risk: low
Aspira Women's Health Inc. announced on September 2, 2025, the departure of Director Dr. Jonathan M. Gelfond and the appointment of Dr. David L. Smith as a new
Aspira Women's Health Inc. Reports Board and Executive Changes — Jul 15, 2025 Risk: medium
Aspira Women's Health Inc. announced on July 11, 2025, changes related to its board of directors and executive compensation. The filing details the departure of
Aspira Women's Health Files 8-K — Jun 11, 2025 Risk: low
Aspira Women's Health Inc. filed an 8-K on June 11, 2025, reporting other events and financial statements. The filing details the company's corporate structure
Aspira Women's Health Files 8-K on Shareholder Vote Matters — Jun 4, 2025 Risk: medium
Aspira Women's Health Inc. filed an 8-K on June 4, 2025, reporting on matters submitted to a vote of its security holders. The filing details corporate actions
Aspira Women's Health Faces Delisting Concerns — Apr 16, 2025 Risk: high
Aspira Women's Health Inc. filed an 8-K on April 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The filin
Aspira Women's Health Reports Material Agreements & Officer Changes — Apr 8, 2025 Risk: medium
Aspira Women's Health Inc. filed an 8-K on April 8, 2025, reporting on several key events that occurred on April 2, 2025. These include entering into a material
Aspira Women's Health Inc. Reports Board and Executive Changes — Mar 31, 2025 Risk: medium
Aspira Women's Health Inc. announced on March 27, 2025, changes related to its board of directors and executive compensation. The filing details the departure o
Aspira Women's Health Inc. Reports Director and Officer Changes — Mar 25, 2025 Risk: medium
Aspira Women's Health Inc. announced on March 21, 2025, changes related to its board of directors and executive compensation. The filing details the departure o
Aspira Women's Health Reports Officer and Director Changes — Mar 19, 2025 Risk: medium
Aspira Women's Health Inc. filed an 8-K on March 19, 2025, reporting changes as of March 15, 2025. The filing pertains to the departure of directors or certain
Aspira Women's Health Files 8-K for Equity Sale — Mar 11, 2025 Risk: medium
On March 5, 2025, Aspira Women's Health Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, forme
Aspira Women's Health Faces Delisting Notice — Feb 14, 2025 Risk: high
Aspira Women's Health Inc. filed an 8-K on February 14, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of F
Aspira Women's Health Appoints New Directors, Adjusts Executive Pay — Feb 10, 2025 Risk: medium
Aspira Women's Health Inc. announced on February 5, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two ne
Aspira Women's Health Inc. Reports Board and Officer Changes — Jan 31, 2025 Risk: medium
Aspira Women's Health Inc. announced on January 28, 2025, a change in its board of directors. Specifically, the company reported the departure of certain office
Aspira Women's Health Files 8-K — Jan 13, 2025 Risk: low
On January 13, 2025, Aspira Women's Health Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibit
Aspira Women's Health Inc. Reports Board and Officer Changes — Jan 7, 2025 Risk: medium
Aspira Women's Health Inc. announced on January 6, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officer
Aspira Women's Health Faces Delisting Notice — Dec 31, 2024 Risk: high
Aspira Women's Health Inc. filed an 8-K on December 31, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company was fo
Aspira Women's Health Inc. Reports Board and Compensation Changes — Dec 16, 2024 Risk: medium
Aspira Women's Health Inc. announced on December 16, 2024, changes in its board of directors and executive compensation arrangements. The filing details the dep
Aspira Women's Health Files 8-K on Financials — Nov 14, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on November 14, 2024, to report on its results of operations and financial condition. The filing includes financial stat
8-K Filing — Oct 29, 2024
Aspira Women's Health Files 8-K — Oct 24, 2024 Risk: low
On October 24, 2024, Aspira Women's Health Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine updat
Aspira Women's Health Files 8-K — Oct 23, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on October 23, 2024, reporting other events and financial statements. The company, formerly known as Vermillion, Inc., C
Aspira Women's Health Faces Nasdaq Delisting Warning — Oct 18, 2024 Risk: high
Aspira Women's Health Inc. received a notice on October 17, 2024, indicating it failed to meet a continued listing rule or standard for the Nasdaq Capital Marke
Aspira Women's Health Files 8-K — Sep 13, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on September 13, 2024, reporting an event on September 9, 2024. The filing primarily concerns financial statements and e
Aspira Women's Health Files 8-K on Financials — Aug 12, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on August 12, 2024, reporting on its results of operations and financial condition, as well as financial statements and
Aspira Women's Health Files 8-K with Material Agreement — Aug 2, 2024 Risk: low
On August 2, 2024, Aspira Women's Health Inc. filed an 8-K report detailing a material definitive agreement and financial statements. The company, formerly know
Aspira Women's Health Files 8-K with Material Agreement — Jul 31, 2024 Risk: medium
On July 31, 2024, Aspira Women's Health Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
Aspira Women's Health Appoints New CMO, Director — Jul 29, 2024 Risk: medium
Aspira Women's Health Inc. announced on July 25, 2024, the appointment of Dr. Michael J. Nally as Chief Medical Officer and the election of Ms. Karen L. King to
Aspira Women's Health Faces Delisting Concerns — Jul 5, 2024 Risk: high
Aspira Women's Health Inc. filed an 8-K on July 5, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of July 1
Aspira Women's Health Files 8-K on Material Agreements — Jul 2, 2024 Risk: medium
Aspira Women's Health Inc. filed an 8-K on July 2, 2024, reporting on events as of June 30, 2024. The filing indicates a material definitive agreement, unregist
Aspira Women's Health Board Changes — Jun 27, 2024 Risk: low
Aspira Women's Health Inc. announced on June 27, 2024, a change in its board of directors. Specifically, the company reported the departure of Director Dr. Mich
Aspira Women's Health Files 8-K — Jun 14, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on June 14, 2024, reporting an event on June 13, 2024. The filing is categorized under Regulation FD Disclosure and Fina
Aspira Women's Health Appoints New CMO, Adds Director — Jun 7, 2024 Risk: low
Aspira Women's Health Inc. announced on June 6, 2024, the appointment of Dr. Carolann M. Small as Chief Medical Officer and the election of Ms. Jennifer L. Good
Aspira Women's Health Files 8-K on Shareholder Vote and Financials — May 14, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on May 14, 2024, reporting on a submission of matters to a vote of security holders and financial statements. The filing
Aspira Women's Health Files 8-K — Apr 26, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on April 26, 2024, reporting other events and financial statements. The company, formerly known as Vermillion, Inc., Cip
Aspira Women's Health Appoints New CMO, Director — Apr 26, 2024 Risk: medium
Aspira Women's Health Inc. announced on April 22, 2024, the appointment of Dr. Michael W. McNeely as Chief Medical Officer and the election of Ms. Karen L. King
Aspira Women's Health Files 8-K on Financials — Mar 28, 2024 Risk: low
Aspira Women's Health Inc. filed an 8-K on March 28, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
Aspira Women's Health: Leadership Changes Announced — Mar 25, 2024 Risk: medium
Aspira Women's Health Inc. announced on March 20, 2024, the departure of its Chief Medical Officer, Dr. Michael W. Nolen. The company also reported on the elect
Aspira Women's Health: Director Changes & Officer Compensation — Mar 21, 2024 Risk: medium
Aspira Women's Health Inc. announced on March 16, 2024, the departure of Director Dr. Michael J. McNeely and the appointment of Dr. David L. Smith as a new dire
Aspira Women's Health Reports Material Agreements, Equity Sales — Jan 25, 2024
Aspira Women's Health Inc. filed an 8-K on January 25, 2024, reporting a material definitive agreement, results of operations, unregistered sales of equity, and
Aspira Women's Health to Present at J.P. Morgan Healthcare Conference — Jan 5, 2024
Aspira Women's Health Inc. filed an 8-K on January 4, 2024, to disclose that they will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Jan

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX